147 related articles for article (PubMed ID: 30846725)
1. Quantifying Tip60 (Kat5) stratifies breast cancer.
McGuire A; Casey MC; Shalaby A; Kalinina O; Curran C; Webber M; Callagy G; Holian E; Bourke E; Kerin MJ; Brown JAL
Sci Rep; 2019 Mar; 9(1):3819. PubMed ID: 30846725
[TBL] [Abstract][Full Text] [Related]
2. Digging Deeper into Breast Cancer Epigenetics: Insights from Chemical Inhibition of Histone Acetyltransferase TIP60
Idrissou M; Lebert A; Boisnier T; Sanchez A; Houfaf Khoufaf FZ; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
OMICS; 2020 Oct; 24(10):581-591. PubMed ID: 32960142
[TBL] [Abstract][Full Text] [Related]
3. TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer.
Idrissou M; Boisnier T; Sanchez A; Khoufaf FZH; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2020; 17(6):687-694. PubMed ID: 33099470
[TBL] [Abstract][Full Text] [Related]
4. The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair.
Bassi C; Li YT; Khu K; Mateo F; Baniasadi PS; Elia A; Mason J; Stambolic V; Pujana MA; Mak TW; Gorrini C
Cell Death Differ; 2016 Jul; 23(7):1198-208. PubMed ID: 26915295
[TBL] [Abstract][Full Text] [Related]
5. TIP60-miR-22 axis as a prognostic marker of breast cancer progression.
Pandey AK; Zhang Y; Zhang S; Li Y; Tucker-Kellogg G; Yang H; Jha S
Oncotarget; 2015 Dec; 6(38):41290-306. PubMed ID: 26512777
[TBL] [Abstract][Full Text] [Related]
6. Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer.
Casey MC; Prakash A; Holian E; McGuire A; Kalinina O; Shalaby A; Curran C; Webber M; Callagy G; Bourke E; Kerin MJ; Brown JA
BMC Cancer; 2019 Jul; 19(1):712. PubMed ID: 31324173
[TBL] [Abstract][Full Text] [Related]
7. MST1R (RON) expression is a novel prognostic biomarker for metastatic progression in breast cancer patients.
Hunt BG; Wicker CA; Bourn JR; Lower EE; Takiar V; Waltz SE
Breast Cancer Res Treat; 2020 Jun; 181(3):529-540. PubMed ID: 32342233
[TBL] [Abstract][Full Text] [Related]
8. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
11. TIP60 contributes to porcine embryonic development by regulating DNA damage response.
Guo J; Zhou W; Niu YJ; Shin KT; Heo YT; Kim NH; Cui XS
Theriogenology; 2018 Mar; 108():146-152. PubMed ID: 29216538
[TBL] [Abstract][Full Text] [Related]
12. Nuclear Localization Is Not Required for Tip60 Tumor Suppressor Activity in Breast and Lung Cancer Cells.
Ravichandran P; Davis SA; Vashishtha H; Gucwa AL; Ginsburg DS
DNA Cell Biol; 2020 Nov; 39(11):2077-2084. PubMed ID: 33155839
[TBL] [Abstract][Full Text] [Related]
13. TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.
Judes G; Dubois L; Rifaï K; Idrissou M; Mishellany F; Pajon A; Besse S; Daures M; Degoul F; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
Epigenomics; 2018 Nov; 10(11):1415-1430. PubMed ID: 30324811
[TBL] [Abstract][Full Text] [Related]
14. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer.
Laurberg JR; Brems-Eskildsen AS; Nordentoft I; Fristrup N; Schepeler T; Ulhøi BP; Agerbaek M; Hartmann A; Bertz S; Wittlinger M; Fietkau R; Rödel C; Borre M; Jensen JB; Orntoft T; Dyrskjøt L
BJU Int; 2012 Dec; 110(11 Pt C):E1228-36. PubMed ID: 23046361
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer.
Jääskeläinen A; Jukkola A; Haapasaari KM; Auvinen P; Soini Y; Karihtala P
Anticancer Res; 2019 Nov; 39(11):5879-5890. PubMed ID: 31704812
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer using KAT inhibitors to mimic lethal knockouts.
Brown JA; Bourke E; Eriksson LA; Kerin MJ
Biochem Soc Trans; 2016 Aug; 44(4):979-86. PubMed ID: 27528742
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
18. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
19. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
[TBL] [Abstract][Full Text] [Related]
20. Rational design and validation of a Tip60 histone acetyltransferase inhibitor.
Gao C; Bourke E; Scobie M; Famme MA; Koolmeister T; Helleday T; Eriksson LA; Lowndes NF; Brown JA
Sci Rep; 2014 Jun; 4():5372. PubMed ID: 24947938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
